Understanding of these principles and properties has led to many advances in the development of immune checkpoint inhibitors, especially drugs that target PD-1 and PD-L1, and there are now various PD-1/PD-L1 inhibitors that are either approved for the treatment of NSCLC or at different phases of drug development. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.